SUPNHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. hold a median 12-month price target of $60 — +46.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 27 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Supernus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Issuance (38): The company has been issuing shares or taking on financing, diluting existing holders.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SUPN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +46.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 9 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $63 → $67 |
| 19 Dec 2025 | Stifel | Maintains | Hold | — |
| 29 Oct 2025 | B of A Securities | Initiates | Buy | — |
| 23 Oct 2025 | TD Cowen | Maintains | Buy | — |
| 9 Oct 2025 | Piper Sandler | Upgrade | Overweight | — |
| 30 Sept 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 29 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 26 Feb 2025 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 19 Feb 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 11 Sept 2024 | Piper Sandler | Downgrade | Neutral | — |
| 28 Feb 2024 | Piper Sandler | Maintains | Overweight | — |
| 9 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 25 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 10 May 2023 | Piper Sandler | Maintains | Overweight | — |
| 23 Jan 2023 | Piper Sandler | Maintains | Overweight | — |
| 31 Aug 2022 | Piper Sandler | Maintains | Overweight | — |
| 13 Apr 2021 | Jefferies | Upgrade | Buy | — |
| 16 June 2020 | Piper Sandler | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SUPN appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Supernus Pharmaceuticals, Inc. returned −22.4% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 41% of US stocks
Cheaper than 38% of US stocks
Cheaper than 16% of US stocks
Higher than 79% of US stocks
Higher than 67% of US stocks
Higher than 94% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 36% of US stocks
Higher than 45% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Supernus Pharmaceuticals, Inc. has a market value of $2.4B and an enterprise value of $2.0B.
Revenue in the twelve months to 30 June 2026: $830.4M. The latest quarter grew 32.4% year on year.
Net income over the same four quarters: −$109.9M, a −13.2% net margin.
Diluted earnings per share, trailing twelve months: $−1.92.
Free cash flow in the twelve months to 30 June 2026: $18.8M.
Trailing P/E: 40.7×; forward P/E: 9.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Supernus Pharmaceuticals, Inc. employs 778 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Supernus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reports that Supernus Pharmaceuticals lacks the two key ingredients it considers associated with a likely earnings beat ahead of the company’s Q3 report.
Why it matters — The preview offers SUPN watchers a brief indication of Zacks’ expectations for the upcoming earnings report.
Supernus said the FDA recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for treating motor fluctuations in adults with advanced Parkinson’s disease. The company also submitted a supplemental application seeking approval of a second supplier, with potential approval by mid-2027.
Why it matters — The exclusivity recognition and pending second-supplier application are relevant regulatory and supply updates for a Supernus product.
Supernus Pharmaceuticals said it will report its third-quarter 2026 financial and business results after market close on October 29, 2026.
Why it matters — SUPN watchers can note the date when the company plans to share its quarterly results and business update.
The article says Supernus’s merger with Indivior gives it operational control and exposure to a larger CNS and addiction platform. It cites growth products at 80% of revenue and describes combined-entity targets of $2.2 billion in revenue, $888 million in adjusted EBITDA, and $125 million in synergies.
Why it matters — SUPN watchers may follow how the merger changes the company’s product mix, scale, and operating profile.
Kahn Swick & Foti, LLC is investigating the proposed sale of Supernus Pharmaceuticals to Indivior Pharmaceuticals, under which Supernus shareholders would receive 1.5401 Indivior shares per Supernus share. The firm is examining the adequacy of the price and process in the proposed transaction.
Why it matters — An investigation into the adequacy of the deal's price and process could affect whether the proposed sale of Supernus to Indivior proceeds as announced.
The 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. have a median 12-month price target of $60, with estimates ranging from $55 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Supernus Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Supernus Pharmaceuticals, Inc. 71 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Supernus Pharmaceuticals, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +46.6% from the last close, and Ticker Nerd's factor model ranks Supernus Pharmaceuticals, Inc. 71 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Supernus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SUPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $67 over the next 12 months.
Supernus Pharmaceuticals, Inc. returned -22.4% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases.
The most recent item we track (Zacks Investment Research, 22 Oct 2026): "Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline". Zacks Investment Research reports that Supernus Pharmaceuticals lacks the two key ingredients it considers associated with a likely earnings beat ahead of the company’s Q3 report.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.
CEO Mr. Jack A. Khattar M.B.A. · 778 employees · United States · https://www.supernus.com
